Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials-Reference-Cited by-同舟云学术

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials

Published:2015-05 Issue:5 Volume:3 Page:356-366
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Udell Jacob A,Cavender Matthew A,Bhatt Deepak L,Chatterjee Saurav,Farkouh Michael E,Scirica Benjamin M

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference66 articles.

1. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored;McMurray;Lancet Diabetes Endocrinol,2014

2. Role of diabetes in congestive heart failure: the Framingham study;Kannel;Am J Cardiol,1974

3. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study;Stratton;BMJ,2000

4. The incidence of congestive heart failure in type 2 diabetes: an update;Nichols;Diabetes Care,2004

5. Glycemic control and heart failure among adult patients with diabetes;Iribarren;Circulation,2001

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering mortality risk of diabetes medications in heart failure patients with diabetes mellitus under triple guideline-directed medical therapy;International Journal of Cardiology;2024-07

2. Roles of non-coding RNA in diabetic cardiomyopathy;Cardiovascular Diabetology;2024-06-29

3. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis;Clinical Research in Cardiology;2024-01-22

4. Engineered Dynamic Hydrogel Niches for the Regulation of Redox Homeostasis in Osteoporosis and Degenerative Endocrine Diseases;Gels;2023-12-30

5. Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials;Journal of Nephrology;2023-12-23